Published in Vaccine Weekly, February 8th, 2006
"Mucosally induced tolerance is an attractive strategy for preventing or reducing autoimmune diseases. We produced a recombinant CTB fusion protein linked with autoantigen T cell epitope of insulin B chain peptide 9-23 (C19S) at levels up to 200 mg/L culture media in Brevibacillus choshinensis secretion-expression system," researchers writing in the journal Biotechnology and Bioengineering report.
"Receptor-competitive assay showed...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2006-02-08)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.